Jazz Pharma reports strong growth
Jazz Pharmaceuticals reported strong growth in its second quarter last week, as revenues rose due to accelerating sales of sleep drug Xyrem and its new anticoagulant defibrotide. The firm reported revenue of $291.2 million, up almost 40 per cent year on year. Jazz also reported adjusted net profit of $128 million, or $2.05 a share, a figure which was ahead of expectations.
Jazz has updated its guidance for the full year, with revenue now...
Subscribe from just €1 for the first month!
Exclusive offers:
All Digital Access + eReader
Trial
€1
Unlimited Access for 1 Month
*New subscribers only
Annual
€200
€149 For the 1st Year
Unlimited Access for 1 Year
Quarterly
€55
€42
90 Day Pass
2 Yearly
€315
€248
Unlimited Access for 2 Years
Team Pass
Get a Business Account for you and your team
Related Stories
The year in review
The best writing and and the biggest stories of 2019 from the Business Post
Newsround: What Thursday’s papers say
Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals
More cycle routes, expansion of Luas to Bray and new bus network proposed
Greater Dublin Area draft Transport Strategy published
